Skip to main content
Equibles
TRAX logo

TRAX · First Tracks Biotherapeutics, Inc.

Track TRAX — free

Use TRAX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TRAX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$33.28 -0.64 (-1.89%) At close · Oct 2
Russell 2000 member Rebalance outlook locked
Market Cap
$1.23B
Shares
35.73M
Volume · Oct 2 1.17M Avg daily vol (3M) 786.99K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$33.28 Open$34.45 Day$32.50–35.41 Available close range$15.32–47.92 Avg vol 30d698K Short int4.5M · 12.6% float · 7.5d Short vol46% DataApr 2026–Oct 2026 Filing10-Q · Aug 12

The closing range uses available history since Apr 6, 2026; less than a full year is stored.

Up next

Latest filing: 10-Q
filed Aug 12, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$168.02M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+21.5%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
12.6%
Latest settlement · 7.5 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Strong Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 15.3 · calm Equity put/call 0.58
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 50-day avg −20%
below
RSI (14) 37
neutral
MACD trend Negative
52-week position 55%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −22%
trailing
6-month return +42%
trailing
Relative strength +29%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+150 funds added
Insider flow Distributing
Net -$1.8M over 90 days · 100% sells
Short interest Rising
12.59% of float · ▲ +11.7% MoM · 7.5 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
150 holders — 13F breadth
Squeeze score 67
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 132%
annualized · 1-yr
Max drawdown −40%
past year
ATR 8.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
−20% Bearish
RSI (14)
37 Neutral
MACD trend
Negative Bearish
52-week position
55% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+150 funds added
Insider flow Distributing
Net -$1.8M over 90 days · 100% sells
Short interest Rising
12.59% of float · ▲ +11.7% MoM · 7.5 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
150 holders — 13F breadth
Price context
position in its available closing range
Range low $15 Now $33 · 55% Range high $48
vs 50-day avg -20%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
TRAX
First Tracks Biotherapeutics, Inc.
this stock
$1.23B — — — 12.6%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +11.3% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -4.8% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +544.3% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
150
% held
95.4%
Net QoQ
+34.1M sh
Top holder
EcoR1 Capital, LLC
Held Float
View
Held by Funds
Fund positions
171
View
Short & Settlement
Short Interest Rising
Shares short
4.5M
Days to cover
7.5d
Change
+469.6K sh
View
Short Volume
Short vol %
46%
As of
Oct 2, 2026
Short Total
View
Fails to Deliver
FTD shares
2
Value
$84
As of
Aug 31, 2026
View
Off-Exchange
Off-exchange %
48.1%
Week of
Aug 24, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$1.8M
Buyers / Sellers
0 / 1
Buyers Sellers
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Sep 9, 2026
This year
9
View
Proposed Sales
Value
$1.8M
Shares
39.3K
Filed
Sep 2, 2026
View
Earnings & Events
Webcasts
Last webcast
Sep 9, 2026
View

Performance

5D 20D 120D MTD YTD
TRAX -3.3% -21.7% +41.6% -6.1% —
SPY -0.2% -0.5% +12.2% +0.9% +12.9%
vs SPY -3.1% -21.3% +29.4% -7.0% —
Key facts CIK 2091349 CUSIP 337185102 13F (30d) 3 filings 3 filers Visit website Investor relations